Kv1.3 channel blockade with the Vm24 scorpion toxin attenuates the CD4+ effector memory T cell response to TCR stimulation

José Ignacio Veytia-Bucheli1,2, Juana María Jiménez-Vargas1, Erika Isabel Melchy-Pérez1, Monserrat Alba Sandoval-Hernández1,2, Lourival Domingos Possani1* and Yvonne Rosenstein1*

Abstract

Background: In T cells, the Kv1.3 and the KCa3.1 potassium channels regulate the membrane potential and calcium homeostasis. Notably, during TEM cell activation, the number of Kv1.3 channels on the cell membrane dramatically increases. Kv1.3 blockade results in inhibition of Ca2+ signaling in TEM cells, thus eliciting an immunomodulatory effect. Among the naturally occurring peptides, the Vm24 toxin from the Mexican scorpion Vaejovis mexicanus is the most potent and selective Kv1.3 channel blocker known, which makes it a promissory candidate for its use in the clinic. We have shown that addition of Vm24 to TCR-activated human T cells inhibits CD25 expression, cell proliferation and reduces delayed-type hypersensitivity reactions in a chronic inflammation model. Here, we used the Vm24 toxin as a tool to investigate the molecular events that follow Kv1.3 blockade specifically on human CD4+ TEM cells as they are actively involved in inflammation and are key mediators of autoimmune diseases.

Methods: We combined cell viability, activation, and multiplex cytokine assays with a proteomic analysis to identify the biological processes affected by Kv1.3 blockade on healthy donors CD4+ TEM cells, following TCR activation in the presence or absence of the Vm24 toxin.

Results: The peptide completely blocked Kv1.3 channels currents without impairing TEM cell viability, and in response to TCR stimulation, it inhibited the expression of the activation markers CD25 and CD40L (but not that of CD69), as well as the secretion of the pro-inflammatory cytokines IFN-γ and TNF and the anti-inflammatory cytokines IL-4, IL-5, IL-9, IL-10, and IL-13. These results, in combination with data from the proteomic analysis, indicate that the biological processes most affected by the blockade of Kv1.3 channels in a T cell activation context were cytokine-cytokine receptor interaction, mRNA processing via spliceosome, response to unfolded proteins and intracellular vesicle transport, targeting the cell protein synthesis machinery.

Conclusions: The Vm24 toxin, a highly specific inhibitor of Kv1.3 channels allowed us to define downstream functions of the Kv1.3 channels in human CD4+ TEM lymphocytes. Blocking Kv1.3 channels profoundly affects the mRNA synthesis machinery, the unfolded protein response and the intracellular vesicle transport, impairing the synthesis and secretion of cytokines in response to TCR engagement, underscoring the role of Kv1.3 channels in regulating TEM lymphocyte function.

Keywords: Kv1.3 potassium channel, Vm24 toxin, Effector memory T cells, Proteomics, Autoimmune disease
Background
Ion transport through ion channels is essential to regulate the membrane potential, the signaling by calcium (Ca$^{2+}$), magnesium, zinc and other divalent cations, as well as downstream events such as gene expression, apoptosis, proliferation, development, and migration [1, 2]. Immune cells express a variety of ion channels and transporters that allow the flux of ions across the plasma membrane and the membrane of intracellular organelles. In T cells, the interaction of the T cell receptor (TCR) with its cognate antigen leads to an increase in the intracellular Ca$^{2+}$ concentration, regulating numerous downstream signaling pathways that control clonal expansion, differentiation and cytokine production [1]. Following intracellular Ca$^{2+}$ stores depletion, the electrochemical potential required for Ca$^{2+}$ entry through Ca$^{2+}$ release-activated Ca$^{2+}$ channels (CRAC) in the plasma membrane is regulated by the efflux of potassium cations to the extracellular space, a process controlled by potassium channels [3]. In T lymphocytes, the voltage-gated potassium channel K$\alpha$1.3 and the calcium-activated potassium channel K$\alpha$3.1 regulate the membrane potential and calcium homeostasis [4] by operating at different levels of the Ca$^{2+}$ signaling pathway. Furthermore, the K$\alpha$.1.3 and the K$\alpha$.3.1 potassium channels cluster with the CRAC calcium channel at the immunological synapse and regulate its function [3, 4]. The K$\alpha$.1.3 channels four identical subunits contain a voltage sensor and are activated by membrane depolarization [5]. Notably, upon activation, the number of K$\alpha$.1.3 channels of effector memory T (TEM) cells dramatically increases, while that of K$\alpha$.3.1 channels remains constant, underscoring a role of K$\alpha$.1.3 channels in the decision making process of TEM lymphocytes [6]. TEM lymphocytes rapidly and copiously produce and release inflammatory and cytotoxic mediators such as IFN-$\gamma$, IL-4, and perforin. They lack CCR7 and CD62L, two receptors involved in homing to the lymph nodes, but the expression of the receptors for inflammatory cytokines CCR1, CCR3 and, CCR5 allows them to recirculate between the blood and inflammatory foci [7–11]. Blocking K$\alpha$.1.3 channels in TEM cells has been reported to reduce the influx of Ca$^{2+}$, resulting in a TEM-specific immunomodulatory effect [4, 12, 13], without compromising naive and central memory T (TCM) lymphocytes’ effector functions, such as protection against pathogens, and T and B cells crosstalk for the generation of high affinity protective antibodies and isotype switching [14, 15]. Autoreactive cells found in multiple sclerosis, rheumatoid arthritis and type I diabetes mellitus lesions exhibit a TEM phenotype and are key mediators in the pathogenesis of these autoimmune diseases [6, 16], stressing the need for restraining these cells.

Potent K$\alpha$.1.3 channel blockers have been found in animal venoms. These molecules interact with the channel though a pharmacophore called “functional dyad”, consisting of a blocking lysine and an aromatic residue located around 7 Å apart. The lysine interacts with acidic residues on the channel selectivity filter, blocking the conduction pore, and preventing the passage of ions through it [17]. Several scorpion toxins (margarotoxin, noxiustoxin, kalitoxin, charybdotoxin, agitoxin-2, OSK1, hongotoxin, anuroctoxin), anemone toxins (ShK) and even peptides from parasitic worms (AcK1, BmK1) have been shown to block the K$\alpha$.1.3 potassium channel with pico- or nanomolar affinities. Particularly, the anemone ShK peptide has been reported to suppress the TEM cell proliferation and pro-inflammatory cytokine secretion without affecting naive or TCM lymphocytes [6, 16, 18]. Unfortunately, these toxins are promiscuous and affect other related potassium channels (K$\alpha$.1.1, K$\alpha$.1.2, K$\alpha$.1.6, K$\alpha$.1.7) necessary for the activity of neurons and muscle cells, eventually causing severe adverse effects and even death [17, 19–24].

Among the naturally occurring peptides, the 36 amino acid toxin Vm24, isolated from the Mexican scorpion Vaejovis mexicanus, is the most potent ($K_d = 2.9$ pM) and selective (> 1500-fold affinity over other assayed potassium channels) K$\alpha$.1.3 channel blocker known, what makes it a very promissory candidate for its use in the clinic [23]. This peptide, similar to other scorpion ion channel modulating toxins, has a cysteine-stabilized α/β structural motif, formed by a short α-helix joined by four disulfide bridges to a triple-stranded antiparallel β-sheet. This structural motif, in combination with the C-terminal amidation, confers stability to the toxin [25]. We have shown that addition of Vm24 to TCR-activated human T cells inhibits calcium-mediated cell signaling and generates a dose-dependent inhibition of CD25 expression and cell proliferation. Furthermore, it reduces delayed-type hypersensitivity reactions in rats in a chronic inflammation model [23]. To achieve a deeper understanding of the role of K$\alpha$.1.3 ion channels in the immune response, to identify the biological processes affected by K$\alpha$.1.3 blockade, and to better characterize the potential pharmacological use of the Vm24 peptide, we evaluated the cytokine secretion and proteomic profiles of CD4$^+$ TEM cells isolated from healthy donors following TCR activation, in the presence or absence of the Vm24 toxin.

Methods
Vm24 and ShK toxins
The Vm24 peptide, the generous gift of Dr. Georgina Gurrola-Briones, was prepared by chemical synthesis.
according to previously published work [25]. The ShK toxin was purchased from Alomone Labs (Jerusalem, Israel).

CD4⁺ TEM lymphocytes purification

This procedure was approved by the Bioethics Committee of the Instituto de Biotecnologia. Buffy coats from anonymized healthy donors were obtained from the Centro Estatal de la Transfusión Sanguínea (Cuernavaca, Morelos, Mexico). Mononuclear cells were separated through Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density gradient centrifugation. Cells obtained were resuspended in RPMI-1640 medium (HyClone, GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal calf serum (By Productos, Guadalajara, Jalisco, Mexico) and incubated in 100 mm tissue-culture plates at 37° C in 5% CO₂ overnight. Non-adherent cells were recovered in arrest medium (RPMI-1640 medium supplemented with 2% fetal calf serum), and incubated in the same medium at 37° C in 5% CO₂ for 24 h. CD4⁺ TEM lymphocytes were purified by magnetic cell sorting (negative selection) with the CD4⁺ Effector Memory T Cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Briefly, non-CD4⁺ TEM cells were labeled with a monoclonal antibody cocktail (biotin-conjugated anti-CD8, CD14, CD15, CD16, CD19, CD34, CD36, CD45RA, CD56, CD123, CD235a, TCRγδ and APC-conjugated anti-CCR7). Subsequently, the preparation was incubated with anti-biotin and anti-APC secondary antibodies conjugated with magnetic MicroBeads. The cell suspension was transferred to an LD Column (Miltenyi Biotec GmbH) placed on a MidiMACS Separator (Miltenyi Biotec GmbH) permanent magnet. The CD4⁺ TEM lymphocytes were recovered by elution, and purity (CD3, CD4, CD45RO and CCR7 expression) was determined by flow cytometry.  

Electrophysiological studies

Blockade of K_{1.3} potassium channels by the Vm24 toxin was evaluated on purified CD4⁺ TEM lymphocytes. Whole-cell currents were measured in voltage-clamped cells using a MultiClamp 700B (Molecular Devices, LLC, Sunnyvale, CA, USA) amplifier connected to a computer with Digidata 1440A (Molecular Devices, LLC) digitizer hardware. For data analysis, the pCLAMP 10 (Molecular Devices, LLC) software package was used. Cells were observed with an Eclipse TS100 (Nikon Instruments Inc., Melville, NY, USA) inverted microscope. Pipettes were pulled from G120 T-4 borosilicate glass capillaries (Warner Instruments, LLC, Hamden, CT, USA) in two stages, which resulted in electrodes with 3 to 5 MΩ resistance in the bath. The bath solution consisted of 145 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 2.5 mM CaCl₂, 5.5 mM glucose and 10 mM HEPES (pH 7.35). The pipette filling solution contained 140 mM KF, 2 mM MgCl₂, 1 mM CaCl₂, 10 mM HEPES and 11 mM EGTA (pH 7.22). For currents measurements from K₁.3 channels, a depolarizing pulse to +50 mV was applied for 14 milliseconds from a holding potential of –120 mV. The protocol was repeated every 15 s. The Vm24 toxin was perfused to the cells at a concentration of 1 nM.

CD4⁺ TEM lymphocytes stimulation

CD4⁺ TEM lymphocytes were divided in five groups: a) unstimulated cells, b) unstimulated cells + Vm24 (1 nM), c) anti-CD3 stimulated cells, d) anti-CD3 stimulated cells + Vm24 (1 nM), and e) anti-CD3 stimulated cells + ShK (1 nM). For TCR-specific stimulation, anti-human CD3ε (clone OKT3, home purified) monoclonal antibody was bound to the surface of 24-well polystyrene cell culture plates at 2 μg/cm², for two hours at 37 °C in phosphate-buffered saline (PBS). Wells were washed three times with PBS to remove the unbound antibody and 1 mL of the cell suspension (1 x 10⁶ cells/mL) per well was plated. When indicated, cells were incubated with the Vm24 or ShK toxins (1 nM) five minutes before the onset of stimulation. Plates were incubated at 37 °C in 5% CO₂ for the indicated times. As experiments were performed with cells from different donors, the expression of the activation marker CD25 (evaluated by flow cytometry) of cells stimulated in the presence or absence of Vm24, was used as internal quality control for all samples.

Cytokine secretion profile

The supernatants from CD4⁺ TEM lymphocytes activated as indicated above were collected, and the secretion of cytokines was evaluated with the LEGENDplex Human Th Cytokine Panel 13-plex (BioLegend, San Diego, CA, USA) and flow cytometry, following the manufacturer’s instructions. Data were collected on a BD FACSCanto II (BD Biosciences, San Jose, CA, USA) flow cytometer with the BD FACSDiva (version 6.1.3, BD Biosciences) software, and analyzed with the LEGENDplex Data Analysis Software (BioLegend).

Quantitative proteomic analysis

The quantitative proteomic analysis was performed on CD4⁺ TEM lymphocytes from three independent donors. Cells from each donor were divided in four conditions (2 x 10⁶ cells/condition): a) unstimulated cells, b) unstimulated cells + Vm24 (1 nM), c) anti-CD3 stimulated cells, and d) anti-CD3 stimulated cells + Vm24 (1 nM), yielding a total of 12 samples. After a 24 h incubation period, cells were washed with PBS and disrupted in 200 μL of lysis solution (2 M urea, 7 M thiourea, 4% CHAPS,
50 mM DTT) supplemented with cOmplete (Roche Diagnostics GmbH, Mannheim, Germany) protease inhibitor cocktail and PhosSTOP (Roche Diagnostics GmbH) phosphatase inhibitor cocktail. The preparations were incubated on ice for 20 min and centrifuged at 17,000 × g at 4 °C for 5 min to remove insoluble material. Total protein in the supernatant was quantified with the 2-D Quant Kit (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA), and 30 μg of protein were taken from each sample and brought to 250 μL with 10× TE buffer (100 mM Tris-HCl, 10 mM EDTA, pH 8.0), 100 μL of 0.3% sodium deoxycholate were added and protein was sequentially precipitated with 72% trichloroacetic acid, followed by 90% acetone as previously reported [26, 27]. Samples were vacuum-dried and sent to the Proteomics Facility of the Institut de Recherches Cliniques (Montreal, Canada). Proteins were reduced with DTT, alkylated with iodoacetamide and digested with trypsin, and the resulting peptides were analyzed by nano-liquid chromatography coupled to tandem mass spectrometry (MS/MS) as previously reported [26, 27]. The Scaffold (version 4.4.7, Proteome Software, Inc., Portland, OR, USA) software was used to validate MS/MS-based peptide and protein identifications. Peptide identifications were accepted if they exceeded the specific database search engine thresholds, calculated as -10log (p), where p is the probability that the observed match between the experimental data and the database sequence is a random event. Mascot (Matrix Science Inc., Boston, MA, USA) identification requires that ion scores be at least greater than the associated identity scores and 20, 15 and 15 for peptides with double, triple, and quadruple charges, respectively. X! Tandem (The Global Proteome Machine, [28]) identifications required at least –log (expected) scores greater than 2.0. Peptide identifications were accepted if they could be established at greater than 95% probability as specified by the PeptideProphet algorithm [29]. Protein identifications were accepted if they could be established at greater than 99% probability [30]. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. For protein quantitation, the exponentially modified protein abundance index (emPAI) value was used [31].

Interaction networks
For protein physical/functional interaction networks identification and functional enrichments specific for Biological Process (GO) and KEGG Pathways, the STRING database (version 10.5, [32]) was used. For interaction networks, proteins were linked based on neighborhood, gene fusion, co-expression, co-occurrence, experimental evidences, existing databases and text-mining criteria with a minimum required interaction score of 0.7 (high confidence).

Flow cytometry
Cell viability was assessed with the Fixable Viability Dye eFluor 780 (Life Technologies, Carlsbad, California, USA). Cells were incubated with the dye (500 μL of a 1:100,000 dilution in PBS) at 4 °C for 30 min in the dark, before analysis by flow cytometry. Changes in forward scatter (FSC) and positive staining with the viability dye were considered as markers of cell death. For fluorescent antibody staining, cells were washed with FACS solution (PBS supplemented with 0.5% bovine serum albumin and 0.1% sodium azide). Fc receptors were blocked with 100 μL of 10% human serum at 4 °C for 30 min, and cells were stained in a 150 μL final volume with the PE anti-human CD3d (clone 7D6, Caltag Laboratories, Burlingame, CA, USA), PerCP anti-human CD3e (clone SK7, BioLegend), TC anti-human CD4 (clone S3.5, Invitrogen Camarillo, CA, USA), PE anti-human CD45RO (clone UCHL1, BioLegend), APC anti-human CCR7 (clone G043H7, BioLegend), APC anti-human CD25 (clone BC96, BioLegend), PE anti-human CD69 (clone FN50, BioLegend), and APC anti-human CD40L (clone 24–31, eBioscience, San Diego, CA, USA) fluorescent antibodies where indicated at 4 °C for 30 min and washed. For IRF4 and Hsp90 detection, cells were fixed with 2% paraformaldehyde in PBS at 37 °C for 10 min, washed and incubated on ice with 500 μL of permeabilization buffer (0.5% Triton X-100, 0.2 μg/mL EDTA and 1% bovine serum albumin in PBS) for 15 min. After removal of the detergent solution, cells were further permeabilized with 90% methanol for an additional hour at −20 °C and stained with PE anti-IRF4 (clone IRF4.3E4, BioLegend) or anti-Hsp90α/β (clone 3H3C27, BioLegend) antibodies, followed by Alexa Fluor 647 goat anti-mouse IgG (Invitrogen, Eugene, OR, USA) second step. Samples were acquired on a BD FACSCanto II (BD Biosciences) flow cytometer with the BD FACSDiva (BD Biosciences) software and analyzed using the FlowJo (version 8.7, FlowJo, LLC, Ashland, OR, USA) software.

Statistical analysis
Data analysis and graphics creation were performed with the OriginPro 7 (OriginLab Corporation, Northampton, MA, USA) software. The heat map was generated using the open-source software MultiExperiment Viewer (version 4.9.0, [33]). For statistical significance, one-way ANOVA test (p < 0.05) was used as a first threshold for differences across treatment groups, followed by a Fisher’s Least Significant Difference (LSD) post-hoc test (p < 0.05).
Results
Kv1.3 channel blockade by the Vm24 toxin does not compromise cell viability but decreases the activation of TEM cells
Kv1.3 is the dominating potassium channel in TEM cells, and a potential target to treat chronic inflammation by selectively compromising TEM cells without undermining the function of naïve and TCM cells that rather depend on the KCa3.1 channels [6]. We previously reported that by specifically blocking the Kv1.3 channel, the Vm24 toxin inhibited T cell activation and proliferation [8]. As these results were obtained with total T cells, here we evaluated the capacity of the Vm24 peptide to specifically inhibit the CD4+ TEM cells function. As a control for Kv1.3 channel blockade, we used the ShK toxin from the Caribbean Sea anemone Stichodactyla helianthus, a recognized Kv1.3 channels inhibitor [21].

CD4+ TEM cells isolated from peripheral blood of healthy donors were positive (>95%) for the CD3, CD4 and CD45RO surface markers and negative for the CCR7 chemokine receptor (Fig. 1a, b). These markers were verified before and after activation, and under all conditions, the terminally differentiated CD4+ TEM cells maintained their phenotype (CD45RO+ and CCR7−), as previously reported [34, 35]. Since the main goal of this study was to perform a functional analysis of TCR-activated TEM cells in the presence of the Vm24 peptide, we first evaluated whether blocking Kv1.3 compromised cell viability.

Following a 24, 48 and 96 h culture period in the presence of the Vm24 peptide or the ShK toxin, CD4+ TEM cells viability was not impaired either in quiescent or OKT3-activated cells. As death positive control, 30% dimethyl sulfoxide (DMSO) was added to the cells for 30 min (Fig. 1c and Additional file 1a, b).

The ability of the synthetic Vm24 toxin to block CD4+ TEM cells Kv1.3 channels was measured by patch clamp in whole cell mode. Consistent with our previous report [23], the Vm24 toxin (1 nM) completely inhibited the Kv1.3 channels current of CD4+ TEM lymphocytes. Moreover, the Kv1.3 channel current was not recovered after a 10 min wash-out period, indicative of the slow

---

**Fig. 1** Kv1.3 channel blockade does not compromise cell viability. Purified CD4+ TEM cells were stained for the (a) CD3, CD4 and (b) CD45RO and CCR7 surface markers. (c) Cell viability was assessed following a 24 h culture period with the Fixable Viability Dye eFluor 780. Changes in FSC and positive staining with the viability dye were considered as cell death markers. For death positive control, 30% dimethyl sulfoxide (DMSO) was added to the cells for 30 min. Data from three independent experiments are shown as mean ± SEM (standard error of mean). (d) Kv1.3 channels currents were measured by patch clamp in whole cell mode. Currents were evoked by a depolarizing pulse to +50 mV from a −120 mV holding potential. The Vm24 toxin was perfused to the cells at a concentration of 1 nM.
dissociation rate of the channel-toxin complex (Fig. 1d). Although concentrations below 100 pM of the Vm24 toxin completely block K_v1.3 currents [23], a 1 nM concentration was used to ensure complete blockade of the channels throughout the entire culture time. Considering that the estimated K_d for K Ca3.1 channels (also present in T cells) is at least 4500-fold higher than that for the K_v1.3 channels [23], it is expected that the remaining current on K Ca3.1 channels is still 95% in the presence of 1 nM Vm24, strongly indicating that the effects observed on the T EM cells result exclusively of K_v1.3 channel blockade.

Finally, we evaluated the effect of blocking K_v1.3 channels on the expression of the early activation markers CD25 (IL2RA), CD40L (CD40LG) and CD69 (CD69) in response to TCR ligation for 24 h. The Vm24 toxin significantly prevented the TCR-mediated CD25 upregulation, similar to the ShK toxin (Fig. 2a, b). Vm24 also prevented the upregulation of CD40L in all subjects (Fig. 2c, d), although this was not statistically significant (p = 0.06). Contrary to what we expected, CD69 upregulation was not affected by Vm24 (Fig. 2e, f), suggesting that the K_v1.3 channels do not participate in the cytoplasm to the plasma membrane translocation of this molecule. Altogether these data indicate that the Vm24 toxin did not compromise cell viability, though it effectively blocked the K_v1.3 channels on T EM cells, resulting in diminished activation.

K_v1.3 channel blockade by the Vm24 toxin decreases the production of pro- and anti-inflammatory cytokines

To characterize the impact of blocking the K_v1.3 channel on TCR activated CD4+ T EM lymphocytes function, we analyzed their cytokine secretion profile in the presence of the Vm24 and ShK peptides. Cells were left unstimulated or were activated for 24 h with plate-bound OKT3 in the presence or absence of the toxins, and the presence of cytokines in the supernatant was evaluated with a multiplex assay. Cytokines that showed at least 1.5-fold change and statistically significant differences (p < 0.05) were identified. Consistent with previous reports [7, 8, 36], stimulating purified CD4+ T EM cells through the TCR induced the secretion of high quantities of the pro-inflammatory cytokine IFN-γ (IFNG) as well as that of the anti-inflammatory cytokines IL-4 (IL4), IL-5 (IL5), IL-9 (IL9), IL-10 (IL10) and IL-13 (IL13), but reduced levels of IL-2 (IL2). The level of the pro-inflammatory cytokine TNF (TNF) was also markedly increased in all samples, yet not in a statistically significant manner, probably reflecting variability between individuals (Fig. 3a). Although CD4+ T EM cells are the principal IL-17-producing population [37], under our experimental conditions (24 h post-OKT3 stimulation), we detected very low levels of IL-17A (IL17A) and IL-17F (IL17F), likely resulting of the fact that this is a family of late expression cytokines, with secretion peaking around day 6 after activation (Fig. 3a). Pairwise comparison between the OKT3 and the OKT3 + Vm24-treated group showed that activating the cells in the presence of the Vm24 toxin resulted in significantly lower levels in the secretion of IFN-γ, IL-4, IL-5, IL-9, IL-10 and IL-13. Vm24 also reduced the TNF increase by at least 50% in all subjects, although this was not statistically significant, probably due also to inter-individual variation (Fig. 3b). Similar to Vm24, the ShK toxin lowered cytokine production resulting of TCR-mediated activation of CD4+ T EM cells.

K_v1.3 channel blockade targets the protein synthesis machinery

To gain a more in-depth view of the role that K_v1.3 channels play in T EM cell activation, we performed a gel-free and label-free mass spectrometry-based quantitative proteomic analysis. As for previous experiments, CD4+ T EM cells from three independent donors were left unstimulated or were activated for 24 h with plate-bound OKT3, both in the presence or absence of the Vm24 toxin. The proteomic analysis yielded 1013 different proteins across the dataset (Additional file 2). Comparison between the four experimental groups using one-way ANOVA (p < 0.05) as a first threshold, uncovered 90 proteins differentially expressed across the dataset. The comparison of the unstimulated and the OKT3-stimulated group detected those proteins with at least 1.5-fold change in either direction that were significantly (p < 0.05) different, and are indicated in the upper right and left segments of the volcano plot (Fig. 4a). Out of the 53 proteins modified upon TCR engagement, 38 were upregulated and 15 were downregulated (Table 1), a list consistent (81.1% agreement) with previously published proteomic data from TCR activated T cells [38, 39]. Within the OKT3-regulated proteins, a pairwise comparison between the OKT3 and the OKT3 + Vm24-treated group identified 27 proteins (red spots in the volcano plot, p < 0.05) affected by K_v1.3 channel blockade in a T cell activation context. Overall, these 27 proteins preserved the same trend of change than when cells were stimulated with OKT3 only. However, the amplitude of the change was reduced, evidencing an inhibition of the TCR-mediated signals as a result of K_v1.3 blockade (Fig. 4a and Table 1).

To gain a wider view of the cellular functions affected by blocking the K_v1.3 channels in a T cell activation context, the 27 proteins were combined with the activation markers and the cytokine data set, to generate a protein-protein interaction network and to perform a functional enrichment analysis with the STRING database. The biological processes most affected by blocking the K_v1.3 channel with the Vm24
toxin in a T cell activation context were cytokine-cytokine receptor interaction, mRNA processing, response to unfolded proteins and intracellular vesicle transport (Fig. 4b).

All proteins in the connected clusters were upregulated upon TCR engagement, and the addition of Vm24 partially prevented their upregulation. This data highlights the role of Kv1.3 channels in reinforcing the TCR-mediated signals, and unravels regulatory functions for these channels in the protein synthesis machinery of T_{EM} cells, further compromising their effector functions at different levels.

Only the TCR-mediated downregulation of four proteins (RPS3A, PDCD4, UBE2N and MYO1F) was prevented by the addition of Vm24 (Fig. 4a upper left segment of the volcano plot and Table 1). These proteins are not part of any of the indicated functional clusters.

The comparison of the unstimulated and the Vm24-only treated group, using the same analytical
criteria (at least 1.5-fold change in either direction and \( p < 0.05 \)), showed that incubating the unstimulated cells with the Vm24 toxin resulted in the upregulation of three proteins and the downregulation of 11 proteins (Additional file 3). Although these proteins are not involved together in a clear canonical biological process according to the enrichment analysis, they participate in transcriptional activation, DNA repair, RNA stability, ribosomal function, and cytokinesis, suggesting that, in resting T EM lymphocytes, \( \text{Kv}1.3 \)-mediated signaling also controls essential biological processes.

To validate the proteomic data set, we analyzed the expression level of interferon regulatory factor 4 (\( \text{IRF4} \)) and heat shock protein 90 (Hsp90), as their expression augmented in a TCR-dependent activation context, and when T cells were activated with OKT3 in the presence of the Vm24 toxin this increase was reduced. IRF4, a transcription factor linking the “cytokine-cytokine receptor interaction” cluster with the “intracellular vesicle transport” and “response to unfolded proteins” clusters, is expressed in all CD4\(^+\) T cell subsets following TCR engagement and it is crucial for cytokine production by effector cells [40]. Hsp90, a fundamental member of the “response to unfolded protein” cluster, participates in the correct folding of the numerous nascent proteins produced during the T lymphocyte effector response and in the regulation of NF-\( \kappa \)B signaling and inflammatory responses [41]. Both, IRF4 (Fig. 4c and Additional file 4a) and Hsp90 (Fig. 4d and Additional file 4b) followed the same expression pattern by mass spectrometry and flow cytometry: a marked upregulation following TCR ligation and a partial reduction of this increase in the presence of either Vm24 or ShK toxins, indicating that \( \text{Kv}1.3 \) channel function is important for their upregulation. We also evaluated CD3e (\( \text{CD3E} \)) since TCR stimulation either by antigen, anti-CD3 antibodies, or pharmacological activators of protein kinase C, results in increased TCR-CD3 internalization and therefore, a down-modulation of its surface levels [42, 43]. Under our experimental conditions, the OKT3-dependent T EM cell activation resulted in an almost complete disappearance of CD3e from the T EM cells surface, regardless of the presence of Vm24 or ShK, suggesting that the molecular events regulating CD3e down-modulation are not dependent on the activity of the \( \text{Kv}1.3 \) channels (Fig. 4e and Additional file 4c).

Altogether, our results identified a number of proteins targeted by the \( \text{Kv}1.3 \) channel-dependent signaling in TCR-activated CD4\(^+\) T EM lymphocytes, uncovering regulatory roles for \( \text{Kv}1.3 \) channels in mRNA processing, response to unfolded proteins, intracellular vesicle transport and cytokine-cytokine receptor interaction.

**Discussion**

The potassium channels \( \text{Kv}1.3 \) and \( \text{KCa}3.1 \) promote the sustained Ca\(^{2+} \) influx necessary for complete T cell activation. Particularly, \( \text{Kv}1.3 \) channels are highly expressed...
in T_Em cells and regulate their activity [6]. Inhibition of Kv1.3 channels by pharmacological blockers has been shown to inhibit the Ca^{2+}-dependent response to antigen stimulation and to ameliorate autoimmune diseases such as multiple sclerosis and psoriasis in animal models [13, 44]. In the present study, we used the Vm24
| UniProt KB | Gene    | Protein                                      | Fisher’s LSD (p) US vs. OKT3 | Fisher’s LSD (p) OKT3 vs. OKT3 + Vm24 | Fold change OKT3/US | Fold change OKT3 + Vm24/US | Concordance with other proteomic studies |
|-----------|---------|---------------------------------------------|-----------------------------|---------------------------------------|---------------------|-----------------------------|-----------------------------------------|
| Q15306    | IRF4    | Interferon regulatory factor 4              | 1.4E-06                     | 1.3E-04                               | 13.04              | 6.71                        | 1, 2                                    |
| Q13283    | G3BP1   | Ras GTPase-activating protein-binding protein 1 | 7.5E-06                     | 1.72E-05                              | 3.90               | 1.31                        | 1, 2                                    |
| Q93934    | STRAP   | Serine-threonine kinase receptor-associated protein | 8.98E-06                     | 8.98E-06                              | 13.95              | 1.00                        | 1, 2                                    |
| P14625    | HSP90B1 | Endoplasmin                                  | 5.94E-05                     | 2.39E-04                              | 2.03               | 1.19                        | 1, 2                                    |
| P08238    | HSP90AB1| Heat shock protein HSP 90-beta              | 2.02E-04                     | 1.26E-03                              | 1.94               | 1.23                        | 1, 2                                    |
| P98179    | RBM3    | RNA-binding protein 3                       | 1.49E-04                     | 3.11E-04                              | 243                | 1.15                        | 1, 2                                    |
| P35606    | COPB1   | Coatomer subunit beta'                     | 8.85E-04                     | 1.20E-03                              | 1.90               | 1.04                        | 1, 2                                    |
| Q92598    | HSPH1   | Heat shock protein 105 kDa                  | 5.92E-04                     | 2.44E-02                              | 4.26               | 2.61                        | 1, 2                                    |
| P53618    | COPB1   | Coatomer subunit beta                      | 5.90E-04                     | 1.05E-02                              | 3.67               | 2.05                        | 1, 2                                    |
| P11142    | HSPA8   | Heat shock cognate 71 kDa protein           | 8.09E-04                     | 4.05E-03                              | 1.87               | 1.20                        | 1, 2                                    |
| P31153    | MAT2A   | S-adenosylmethionine synthase isofrom type-2| 1.47E-03                     | 5.27E-03                              | 7.91               | 2.37                        | 1, 2                                    |
| Q27109    | HLA-B   | HLA class I histocompatibility antigen      | 2.08E-03                     | 4.51E-03                              | 2.23               | 1.16                        | 1                                       |
| P62955    | TRAB2   | Transformer-2 protein homolog beta          | 1.43E-03                     | 7.12E-03                              | 3.43               | 1.60                        | 2                                       |
| P11021    | HSPA5   | 78 kDa glucose-regulated protein            | 3.24E-03                     | 1.32E-02                              | 1.62               | 1.14                        | 1, 2                                    |
| O43396    | TXNL1   | Thioredoxin-like protein 1                  | 1.26E-03                     | 3.45E-02                              | 4.61               | 2.72                        | 1, 2                                    |
| Q14103    | HNRNPD  | Heterogeneous nuclear ribonucleoprotein D0   | 5.12E-03                     | 1.60E-02                              | 1.67               | 1.14                        | 2                                       |
| Q13435    | SF3B2   | Splicing factor 3B subunit 2                | 4.02E-03                     | 3.16E-02                              | 3.30               | 1.80                        | 1, 2                                    |
| Q15436    | SEC23A  | Protein transport protein Sec23A            | 5.22E-03                     | 2.28E-02                              | 3.64               | 1.69                        | 2                                       |
| Q07666    | KHDRBS1 | KH domain-containing, RNA-binding, signal transduction-associated protein 1 | 1.0E-02                     | 8.73E-03                              | 2.36               | 0.96                        | 2                                       |
| Q16629    | SRSF7   | Serine/arginine-rich splicing factor 7       | 1.28E-02                     | 1.56E-02                              | 2.99               | 1.08                        | 2                                       |
| P08195    | SLC3A2  | 4F2 cell-surface antigen heavy chain        | 9.01E-05                     | 1.88E-02                              | 9.94               | 6.31                        | 1, 2                                    |
| O94925    | GLS     | Glutaminase kidney isofrom, mitochondrial   | 1.59E-04                     | 4.37E-02                              | 6.80               | 4.72                        | 2                                       |
| P23381    | WARS    | Tryptophan--tRNA ligase, cytoplasmic        | 8.15E-04                     | 4.82E-02                              | 5.32               | 3.39                        | 1, 2                                    |
| O60763    | UOS1    | General vesicular transport factor p115     | 1.07E-03                     | 1.31E-01                              | 3.15               | 2.42                        | 2                                       |
| P42224    | STAT1   | Signal transducer and activator of transcription 1-alpha/beta | 2.48E-03                     | 1.26E-01                              | 2.98               | 2.20                        | 2                                       |
| P10515    | DLAT    | Dihydrolipoic acid residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial | 1.75E-03                     | 9.08E-02                              | 5.30               | 3.50                        | 2                                       |
| P23246    | SFPO    | Splicing factor, proline- and glutamine-rich | 3.63E-03                     | 3.23E-01                              | 1.59               | 1.44                        | 2                                       |
| O00571    | DDX3X   | ATP-dependent RNA helicase DDX3X            | 1.07E-02                     | 2.31E-01                              | 3.43               | 2.48                        | 1, 2                                    |
| P24534    | EEF1B2  | Elongation factor 1-beta                   | 4.62E-02                     | 1.9E-01                              | 1.54               | 1.88                        | 1, 2                                    |
| P17980    | PSMC3   | 26S proteasome regulatory subunit 6A        | 3.69E-02                     | 9.95E-01                              | 1.74               | 1.73                        | 1, 2                                    |
| P27708    | CAD     | CAD protein                                 | 6.06E-03                     | 1.14E-01                              | 1.93               | 1.48                        | 1, 2                                    |
| P17987    | TCP1    | T-complex protein 1 subunit alpha           | 1.98E-02                     | 3.51E-01                              | 2.58               | 2.04                        | 1, 2                                    |
| Q99613    | EIF3C   | Eukaryotic translation initiation factor 3 subunit C | 3.55E-03                     | 5.77E-02                              | 3.33               | 2.06                        | 1, 2                                    |
| Q9UN86    | G3BP2   | Ras GTase-activating protein-binding protein 2 | 9.56E-03                     | 1.17E-01                              | 3.20               | 2.06                        | 1, 2                                    |
| P67809    | YBX1    | Nuclease-sensitive element-binding protein 1| 1.61E-02                     | 7.19E-02                              | 2.02               | 1.32                        | 1, 2                                    |
| P26641    | EEF1G   | Elongation factor 1-gamma                  | 2.7E-02                      | 8E-02                                | 1.76               | 1.20                        | 1, 2                                    |
| P34932    | HSPA4   | Heat shock 70 kDa protein 4                | 1.93E-02                     | 9.42E-02                              | 2.17               | 1.41                        | 1, 2                                    |
| P11940    | PABPC1  | 40S ribosomal protein S3a                   | 1.15E-05                     | 7.50E-02                              | 2.92               | 2.51                        | 1, 2                                    |
| P61088    | UBE2N   | Ubiquitin-conjugating enzyme E2 N          | 4.75E-02                     | 1.82E-03                              | 0.50               | 1.48                        | –                                       |
| P61247    | RPS3A   | 40S ribosomal protein S3a                   | 1.48E-03                     | 1.65E-02                              | 0.42               | 0.79                        | –                                       |
toxin, a highly specific blocker of the K_{v}1.3 channels to identify the cellular processes that depend on the activity of these channels in TCR-activated human T^{EM} lymphocytes as well as to validate the use of the Vm24 peptide to downregulate T^{EM} cell function.

Consistent with previous reports [23], and with the high dependency of T^{EM} lymphocytes on K_{v}1.3 channel function for sustained activation, the addition of Vm24 to CD3-activated T^{EM} lymphocytes resulted in a pronounced inhibition of CD25 and CD40L expression, probably as a consequence of the lack of activation of calcineurin and the subsequent translocation of the NFAT transcription factor to the CD25 and CD40L promoters [45] [46]. Interestingly, under our experimental conditions, Vm24 did not prevent the OKT3-induced expression of CD69, a negative regulator of chronic inflammation [47, 48].

In consonance with the inhibition of the expression of early activation markers, the addition of the Vm24 peptide to OKT3-activated T^{EM} lymphocytes inhibited the secretion of the pro-inflammatory cytokines IFN-γ and TNF, as well as that of the Th2 cytokines IL-4, IL-5, IL-9, IL-10 and IL-13, all of which are dependent on the availability of NFAT [49–59].

We previously reported that administration of the Vm24 peptide lessened the severity of inflammation in a delayed-type hypersensitivity model [23]. Other studies in animal models of human diseases (allergic asthma, experimental autoimmune encephalomyelitis) have shown that the abatement of the K_{v}1.3 channel currents in vivo (by knocking out the channel or by treatment with ShK derivatives) ameliorates the progression of the disease and decreases the production of the effector cytokines IFN-γ, IL-4, IL-5 and IL-17, but enhances that of the anti-inflammatory cytokine IL-10 [60, 61]. Contrary to these reports, under our experimental conditions, the blockade of K_{v}1.3 channels in isolated human CD4^{+} T^{EM} cells from healthy donors reduced IL-10 production, consistent with a downstream inhibition of NFATc2 and IRF4 recruitment, two transcription factors that synergistically augment the activity of the Th2-specific enhancer CNS-9 (a cis-regulatory element upstream of the IL-10 gene locus) [62, 63]. Whether this discrepancy reflects species-specific differences or differences that result from different experimental settings (knocking out the channel or an in vivo T cell activation versus in vitro anti-CD3 CD4^{+} T^{EM} activation) remains to be investigated.

Also, it is important to consider that although IL-4, IL-5, IL-10 and IL-13 are classified as anti-inflammatory...
cytokines due to their down-modulatory effect on inflammatory phenomena mediated by Th1/Th17 cells, these cytokines mediate type I hypersensitivity inflammatory conditions and significantly contribute to the pathogenesis mediated by immune complexes, through their important effect on the activation and proliferation of B cells and antibody synthesis [64].

Furthermore, consistent with the fact that the signaling pathways that activate the transcription of those genes are also dependent on NFAT availability, our data suggest that the inhibition of the K\textsubscript{1,3} channel exerts a down-regulatory effect on the different T\textsubscript{EM} lymphocyte subsets, including Th1 and Th2 cells. In this regard, it would be expected that K\textsubscript{1,3} blockers could act as a wide spectrum immunosuppressive molecule, with a significant effect on different immune-mediated conditions.

The proteomic analysis revealed that, in agreement with the large secretory demand of TCR-activated T\textsubscript{EM} cells, the protein synthesis machinery is prepared to generate a robust immune response by regulating the expression level of transcription factors specific for inflammatory mediators, such as IRF4, as well as that of proteins involved in the splicing machinery, the unfolded protein response and vesicular transport of the novel synthesized mediators. IRF4 is expressed across all T cell subsets within a few hours following TCR engagement, and it is necessary for optimal T cell proliferation in response to mitogenic stimuli. In cooperation with transcriptional partners such as NFAT, it controls the expression of IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17, IL-21, IFN-\gamma and TNF [40, 65–67]. Furthermore, the calcineurin inhibitor cyclosporine A [65] as well as defects in CRAC channels function [68] result in impaired IRF4 expression, implicating NFAT in IRF4 upregulation. Our data show that in a T cell activation context, the expression level of IRF4 is diminished following Vm24 treatment, suggesting that blocking the K\textsubscript{1,3} channel hinders downstream events such as NFAT activation and IRF4 expression, resulting in impaired cytokine production, in consonance with a previously assigned function for K\textsubscript{1,3}-dependent signals in secretory functions [14, 69].

The unfolded protein response allows cells to manage the endoplasmic reticulum stress resulting of the increased folding demand imposed by the requirements of activated T lymphocytes engaged in secretory functions. Especially, the molecular chaperone Hsp90 regulates the stability and function of IRE1, an endoplasmic reticulum transmembrane kinase that activates the unfolded protein response to maintain the endoplasmic reticulum function [70]. Upon treatment with the Vm24 peptide or the ShK toxin, the expression level of the Hsp90 chaperone as well as that of other members of the heat shock family of proteins was strongly diminished. In addition, we found that K\textsubscript{1,3} channels-dependent signals are necessary for the up-regulation of the amino acid transporter SLC3A2. Nutrient transporters such as SLC3A2 ensure and coordinate the supply of nutrients necessary for the increased metabolic requirements of effector lymphocytes. Thus, K\textsubscript{1,3} channels participate in regulating basic metabolic requirements in T\textsubscript{EM} cells. In concordance with our results, a recent proteomic study performed on activated microglia also revealed that blocking K\textsubscript{1,3} channels attenuates biological processes related to the regulation of the immune response and the intracellular protein transport [71]. Assessing if this extends to other cell types becomes critical to appreciate better the potential side effects of blocking the K\textsubscript{1,3} channels to control autoimmune disorders.

Interestingly, we found that blocking the K\textsubscript{1,3} channels with Vm24 on OKT3-activated CD4+ T\textsubscript{EM} cells does not entirely block the anti-CD3 induced cytokines synthesis or proteomic changes; it prevents the changes from reaching the highest level. Residual potassium fluxes from the few K\textsubscript{Ca3.1} channels present on these cells may contribute to the “incomplete” inhibition [35]. In support of the relative abundance of K\textsubscript{1,3} channels as compared to that of K\textsubscript{Ca3.1} channels on T\textsubscript{EM} cells, our data indicate that K\textsubscript{1,3} channels are the major providers of potassium efflux; they are not dispensable for CD4+ T\textsubscript{EM} cell response, yet they are central for regulating the amplitude of the response.

Although less is known about the function of the K\textsubscript{1,3} channels in human CD8+ cells, the decrease of K\textsubscript{1,3} currents by genetic or pharmacological approaches inhibits the differentiation of T\textsubscript{CM} to T\textsubscript{EM} cells and in the latter, it severely impairs the proliferation, the secretion of IL-2, TNF and granzyme B (but not of IFN-\gamma), ultimately dampening their ability to kill target cells [69, 72]. Interestingly, NFATc1-deficient CD8+ T cells show diminished RNA levels of granzyme B and of genes encoding cytokines and chemokines in addition to genes controlling glycolysis [73], further underscoring the importance of K\textsubscript{1,3} channels on the calcium/calcineurin/NFAT network.

In addition to exploring the function of K\textsubscript{1,3} channels in activated CD4+ T\textsubscript{EM} cells, the experiments we performed allowed us to compare the efficacy of two K\textsubscript{1,3} channel blockers: the Vm24 toxin, isolated from the Mexican scorpion Vaejovis mexicanus and the ShK toxin, from the sea anemone Stichodactyla helianthus. Their capacity to hinder T\textsubscript{EM} cells functions showed that both toxins were very effective to block the K\textsubscript{1,3} potassium channels-dependent signaling as they both inhibited the production of INF-\gamma, TNF, IL-4, IL-5, IL9, IL10 and IL13 following TCR ligation. Although not statistically significant, the inhibitory capacity of the ShK peptide was always higher than that of Vm24. The ShK peptide is a very potent (K\textsubscript{d} = 10 pM) K\textsubscript{1,3} blocker.
However, it has a low selectivity for the K$_{v1.3}$ channels (only 2.8-fold affinity over other channels), as a result of which it is very toxic to mammals [21, 74]. Dalazatide$^*$ (formerly ShK-186), a molecule derived from the ShK toxin, is a K$_{v1.3}$ channel blocker that has gone into clinical phase trials, has been shown to reduce the levels of plasmatic and T$_{EM}$ inflammation markers, and to improve psoriatic skin lesions from mild to moderate plaque psoriasis patients [13, 16, 75]. In comparison with Dalazatide$^*$, the Vm24 peptide has the advantage of a greater potency (K$_D$ 2.9 vs. 69 pM) and selectivity (1500 vs. 100-fold affinity over other channels) towards K$_{v1.3}$ channels [21, 23], which improves the safety index in conditions where the blood-brain barrier (such as multiple sclerosis) is compromised and the presence of high concentrations of non-specific blockers (such as neuronal K$_{v1.1}$ channels blockers) in the central nervous system can bring severe neurotoxicity. Interestingly, although Dalazatide$^*$ was well tolerated during clinical trials, the most common adverse events were temporary hypoesthesia and paresthesia involving hands, feet, or perioral area which may be prevented with more selective K$_{v1.3}$ blockers such as Vm24 or other second-generation blockers derived from ShK toxin that have been recently developed [76].

Conclusions
Our results show that blocking K$_{v1.3}$ channels with the Vm24 peptide profoundly affects the mRNA synthesis machinery, the unfolded protein response and the intracellular vesicle transport, thus impairing the synthesis and secretion of cytokines in response to TCR engagement, highlighting the importance of K$_{v1.3}$ channels for T$_{EM}$ cell function. As T$_{EM}$ cells are considered to be main players in the pathology of autoimmune diseases, further studies are needed to better characterize the molecular mechanisms affected by the blockade of K$_{v1.3}$ channels by toxins such as the Vm24 peptide.

Additional files

**Additional file 1:** K$_{v1.3}$ channel blockade does not compromise cell viability. (a) Cell viability of cells treated under the same experimental conditions as for Fig. 1 was assessed following a 24, 48 and 96 h culture period with the Fixable Viability Dye eFluor 780. The dot plot of a representative donor after 24 h of culture is shown. Changes in forward scatter (FSC) and positive staining with the viability dye were considered as cell death markers. As death positive control, 30% dimethyl sulfoxide (DMSO) was added to the cells for 30 min. The cell death area is enclosed in the gate. (b) Data from three independent experiments with CD4$^+$ T$_{EM}$ cells from independent donors are shown as mean ± SEM. (TIF 6948 kb)

**Additional file 2:** Proteins identified in the mass spectrometry-based quantitative proteomic analysis. Peptide identifications were accepted if they could be established at greater than 95% probability as specified by the PeptideProphet algorithm. Protein identifications were accepted if they could be established at greater than 99% probability. (XLSX 427 kb)

**Additional file 3:** Proteins differentially expressed when incubating the unstimulated cells with the Vm24 toxin. Proteins identified with the mass spectrometry-based quantitative proteomic analysis, with at least 1.5-fold change in either direction and that were significantly ($p < 0.05$) different, comparing the unstimulated and the Vm24-treated group. (PDF 150 kb)

**Additional file 4:** Validation of proteomic analysis results by flow cytometry. CD4$^+$ T$_{EM}$ cells were stimulated through the TCR with plate-bound OKT3 in the presence or absence of Vm24 or ShK (1 nM) toxins, as indicated in the methods section. After 24 h of culture, cells were stained for (a) IRF4, (b) Hsp90 and (c) CD3e. The histogram of one representative donor for each staining is shown. (TIF 4252 kb)

**Abbreviations**
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; CRAC: Ca$^{2+}$ release-activated Ca$^{2+}$ channels; DMSO: Dimethyl sulfoxide; emPAI: Exponentially modified protein abundance index; Fisher’s LSD: Fisher’s Least Significant Difference post-hoc test; FSC: Forward scatter; Hsp90: Heat shock protein 90; IRE1: Serine/threonine-protein kinase/endoribonuclease IRE1; IRF4: Interferon regulatory factor 4; K$_D$: Dissociation constant; MS/MS: Tandem mass spectrometry; NFAT: Nuclear factor of activated T-cells; SEM: Standard error of mean; TCR: T cell receptor; T$_{EM}$ Effector memory T cells.

Acknowledgements
The authors are indebted to Dr. Georgina Gurrola-Brones for the generous gift of the Vm24 toxin used in this work and to Dr. Rita Restano-Cassulini for support during the electrophysiological (patch clamp) experiments with Vm24. The authors thank Dr. Denis Faubert and Dr. Rosario Vera-Estrella for their helpful suggestions for MS analysis and Estefanía Alemán-Navarro, M. Sc., María Teresa Romero-Gutierrez, M. Sc., Dr. Ernesto Ortiz, and Dr. Roberto González-Amaro for help with data analysis. JIV is the recipient of a graduate student fellowship from CONACYT (fellowship holder number 289448).

Funding
This work was partially supported by grants from the Consejo Nacional de Ciencia y Tecnología (CONACYT) SEP-CONACYT 237864 (LDP) and SEP-CONACYT 220990 (YR). The funding sources had no role in the design of the study, in collection, analysis, and interpretation of the data or in writing of the manuscript.

Authors’ contributions
JIVB, JMJV, LDP and YR designed the experiments and wrote the manuscript with input from all other authors; JIVB and EIMP conducted the experiments; JIVB, JMJV, MASH and YR undertook the analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The Vm24 peptide and its use are protected by an international patent application WO2008139243 A1 in the name of Universidad Nacional Autónoma de México (UNAM). The same subject was protected in several countries. In addition, a license was granted to a Mexican pharmaceutical company for commercial exploitation; however, the authors kept the right to continuing research in the field involving this peptide. The financing of this work came from the declared funding institutions only. No other possible conflicts of interest are involved.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Departamento de Medicina Molecular y Bioprocessos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Av. Universidad
References

1. Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. Annu Rev Immunol. 2015;33:291–333.
2. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev. 2009;231:59–87.
3. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol. 2007;7:690–702.
4. George Chandy K, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci. 2004;25:280–9.
5. Gutman GA. International Union of Pharmacology. LII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev. 2005;57:473–508.
6. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, et al. The voltage-gated Kv1.3 K+ channel in effector memory T cells as a new target for MS. J Clin Invest. 2003;111:1703–13.
7. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–13.
8. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745–63.
9. Reinhart RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature. 2001;410:101–5.
10. Schenkel JM, Masopust D, Tissue-resident memory T cells. Immunity. 2014;41:886–97.
11. Gerlach C, Moseman EA, Loughhead SM, Alvarez D, Zwijnenburg AJ, Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity. 2014;41:291–8.
12. Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel A-M, Gola M, et al. Selective blockage of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001;166:936–44.
13. Tarcha EJ, Chi V, Munoz-Elias EJ, Bailey D, Londono LM, Upadhyay SK, et al. Durable pharmacological responses from the peptide Shk-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease. J Pharmacol Exp Ther. 2013;344:262–53.
14. Beeton C. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005;67:1369–81.
15. Matheu MP, Beeton C, Garcia A, Chi V, Ranagaraju S, Safrina G, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008;29:602–14.
16. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci. 2006;103:17414–9.
17. Quinteno-Hernández V, Jiménez-Vargas JM, Gurrula GB, Valdivia HH, Possani LD. Scorpion venom components that affect ion-channels function. Toxicon. 2013;76:328–42.
18. Hu L, Pennington M, Jiang Q, Whartenby KA, Calabresi PA. Characterization of the Functional Properties of the Voltage-Gated Potassium Channel Kv1.3 in Human CD4+ T Lymphocytes. J Immunol. 2007;179:4563–70.
19. Carbone E, Waniek E, Prestipino G, Possani LD, Maelicke A. Selective blockage of voltage-dependent K+ channels by a novel scorpion toxin. Nature. 1982;296:90–1.
20. Chhabra S, Chang SC, Nguyen HM, Hux R, Tanner MR, Londono LM, et al. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014;28:3952–64.
21. Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, et al. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon. 2012;59:529–46.
22. Grüssmer S, Nguyen AN, Aiyar J, Hanson DC, Mathei R, Gutman GA, et al. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994;45:1227–34.
23. Varga Z, Gurrula-Biones G, Papp F, de la Vega RC, Pedraza-Alva G, Tajhya RB, et al. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells. Mol Pharmacol. 2012;82:372–82.
24. Wulff H, Castle NA, Parodi LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8:3962–1001.
25. Gurrula GB, Hernández-López RA, de la Vega RC, Varga Z, CVF B, Salas-Castillo SP, et al. Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes. Biochemistry. 2012;51:4049–61.
26. Barkla BJ, Vera-Estrella R, Pantoja O. Protein profiling of epidermal bladder cells from the holohyphic Membranethamnium crystallinum. Proteomics. 2012;12:2862–5.
27. Murillo A, Vera-Estrella R, Barkla BJ, Méndez E, Arias CF. Identification of host cell factors associated with Astrovirus replication in Caco-2 cells. J Virol. 2015;89:10359–70.
28. Beavis RC. Using the global proteome machine for protein identification. In: Nedelkov D, Nelson RW, editors. New and emerging proteomic techniques. New Jersey: Humana Press; 2006. p. 217–28.
29. Keller A, Neszvitszki AI, Kolker E, Aebesfeld R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem. 2002;74:5383–92.
30. Neszvitszki AI, Keller A, Kolker E, Aebesfeld R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003;75:4646–58.
31. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappislier J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomes by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005;4:1267–75.
32. Saldarczyk D, Franceschini A, Wyder S, Forslund K, Keller D, Huerta-Cepas J, et al. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52.
33. Howe E, Holton K, Nair S, Schlauch D, Sinha R, Quackenbush J. Biomedical Informatics for Cancer Research. In: Ochs MF, Casagrande JT, Davuluri RV, editors; Biomedical Informatics for Cancer Research. Boston, MA: Springer US; 2010. p. 267–277.
34. Li Y, Kurlander RJ. Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med. 2010;8:104.
35. Chiang EY, Li T, Jeet S, Peng J, Zhang J, Lee WP, et al. Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions. Nat Commun. 2017;8:14644.
36. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14:242–35.
37. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol. 2008;180:7948–57.
38. Tan H, Yang K, Li Y, Shaw TI, Wang Y, Blanco DB, et al. Integrative proteomics and Phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation. Immunity. 2017;46:488–503.
39. Ron-Harel N, Santos D, Ghergurovic JM, Sage PT, Reddy A, Lovtich SB, et al. Mitochondrial biogenesis and proteome remodeling promote one-carbon metabolism for T cell activation. Cell Metab. 2016;24:104–17.
40. Huber M, Lohoff M. IRF4 at the crossroads of effector T cell fate decision. J Immunol. 2014;194:1886–95.
41. Knowletton AA. NFκB, heat shock proteins, HSF-1, and inflammation. Cardiovasc Res. 2006;69:67–8.
42. Boyer C, Auphan N, Luton F, Malburet J-M, Barad M, Bizozzero J-P, et al. T cell receptor/CD3 complex internalization following activation of a cytolytic T cell clone: evidence for a protein kinase C-independent staurosporine-sensitive step. Eur J Immunol. 1991;21:1623–34.
43. José ES, Borotto A, Niedergang F, Alcover A, Alarcón B. Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. Immunity. 2000;12:161–70.
44. Kundu-Raychaudhuri S, Chen Y-J, Wulff H, Raychaudhuri SP. Kv1.3 in psooriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective
in the SCID mouse psoriasis – Xenograft model. J Autoimmun. 2014;55:63–72.

45. Schuh K, Twadzik D, Kneitz B, Heyer J, Schimpf A, Serfling E. The interleukin 2 receptor a chain/CD25 promoter is a target for nuclear factor of activated T cells. J Exp Med. 1998;188:1369–73.

46. Tjytstykova AV, Tutsukov EN, Ghea RS. The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J Biol Chem. 1996;271:3763–70.

47. Martin P, Gómez M, Lamana A, Marín AM, Cortés JR, Ramírez-Huesca M, et al. The leucocyte activation antigen CD69 limits allergic asthma and skin contact hypersensitivity. J Allergy Clin Immunol. 2010;126:355–63.e3.

48. Sancho D, Gómez M, Sánchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005;26:36–40.

49. Sica A, Dorman L, Viggiano V, Cippettii M, Ghosh P, Rice N, et al. Interaction of NF-κB and NFAT with the interferon-γ promoter. J Biol Chem. 1997;272:30412–20.

50. Kaminuma O, Kitamura F, Kitamura N, Hiroi T, Miyoshi H, Miyawaki A, et al. NF-κB activation in CD14+ monocytes is critical for the early amplification of inflammatory cytokines. J Immunol. 1994;153:625–30.

51. Rooney JW, Hodge MR, McCaffrey PG, Rao A, Glimcher LH. A common NF-Y and NF-ATc. Mol Cell Biol. 1993;13:4793–804.

52. McCaffrey PG, Goldfeld AE, Rao A. The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-α gene transcription. J Biol Chem. 1994;269:30445–50.

53. Szabo SJ, Gold JS, Murphy TL, Murphy KM. Identification of cis-acting regulatory elements controlling interleukin-4 gene expression in T cells: roles for NF-Y and NF-ATc. Mol Cell Biol. 1993;13:4793–805.

54. Chunplo S, Schomberg C, Gerwig R, Heinfling A, Reeves R, Grummt F, et al. Multiple closely-linked NFATc1/cis-regulatory binding sites are part of the interleukin-4 promoter. Nucleic Acids Res. 1993;21:5694–704.

55. Rooney JW, Hodge MR, McCaffrey PG, Rao A, Glimcher LH. A common factor regulates both Th1- and Th2-specific cytokine gene expression. EMBO J. 1994;13:625–33.

56. Stranick KS, Zambas DN, Uss AS, Egan RW, Billah MM, Umland SP. Identification of transcription factor binding sites important in the regulation of the human Interleukin-1 gene. J Biol Chem. 1997;272:16453–65.

57. Lee HJ, Masuda ES, Arai N, Arai K, Yokota T. Definition of cis-regulatory elements of the mouse Interleukin-1 gene promoter. J Biol Chem. 1995;270:17541–50.

58. Jash A, Sahoo A, Kim G-C, Chae C-S, Hwang J-S, Kim J-E, et al. Nuclear factor of activated T cells regulates both Th1- and Th2-specific cytokine gene expression. J Biol Chem. 2004;279:12623–32.

59. Lee C-G, Kang K-H, So J-S, Kwon H-K, Son J-S, Song M-K, et al. A distal cis-regulatory element of the mouse Interleukin-5 gene promoter. J Biol Chem. 1995;270:30412–5.

60. Jash A, Sahoo A, Kim G-C, Chae C-S, Hwang J-S, Kim J-E, et al. Nuclear factor of activated T cells facilitates nuclear factor-kappaB (NF-kB)-mediated Interleukin-9 (IL-9) transactivation. J Biol Chem. 2012;287:15445–57.

61. Macian F. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J. 2000;19:4783–95.

62. Gocke AR, Lebbon LA, Grishkan N, Hu L, Nguyen HM, Whartenby KA, et al. Kv1.3 deletion biases T cells toward an Immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis. J Immunol. 2012;188:5877–86.

63. Koshy S, Huq R, Tanner MR, Atik MA, Porter PC, Khan FS, et al. Blocking Kv 1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014;289:12623–32.

64. Lee C-G, Kang K-H, So J-S, Kwon H-K, Son J-S, Song M-K, et al. A distal cis-regulatory element, CNS-9, controls NFAT1 and IRF4-mediated IL-10 gene activation in T helper cells. Mol Immunol. 2009;46:613–21.

65. Shachar I, Karin N. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol. 2013;93:51–61.

66. Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? Immunol Rev. 2010;233:79–96.

67. Raczkowski F, Ritter J, Heesch K, Schumacher V, Gurakic A, Hacker L, et al. The transcription factor interferon regulatory factor 4 is required for the generation of protective effector CD8+ T cells. Proc Natl Acad Sci. 2013;110:15019–24.

68. Vaeth M, Eckstein M, Shaw PJ, Kozhaya L, Yang J, Berberich-Siebelt F, et al. Store-operated Ca2+ entry in follicular T cells controls Humoral immune responses and autoimmunity. Immunol. 2016;64:1350–64.

69. Hu L, Wang T, Gocke AR, Nath A, Zhang H, Margolick JB, et al. Blockade of Kv1.3 potassium channels inhibits differentiation and Granulocyte M colony formation of human CD14+ T effector memory lymphocytes. PLoS One. 2013;8:e54267.

70. Grootjans J, Kaser A, Kaufmann RJ, Blumberg RS. The unfolded protein response in immunity and inflammation. Nat Rev Immunol. 2016;16:469–84.

71. Rangaraju S, Raza SA, Pennati A, Deng Q, Dammer EB, Duong D, et al. A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. J Neuroinflammation. 2017;14:128.

72. Sim JH, Kim KS, Park H, Kim K-J, Lin H, Kim T-J, et al. Differentially Expressed Potassium Channels Are Associated with Function of Human Effector Memory CD8+ T Cells. Front Immunol. 2017;8:859.

73. Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Flöter J, et al. NFATc1 controls the cytotoxicity of CD8+ T cells. Nat Commun. 2017;8:511.

74. Cañada-O, Sotolongo V, Amor AM, Stocklin R, Anderson AJ, Harvey AL, et al. Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. Toxicon. 1995;33:603–13.

75. Tarcha EJ, Olsen CM, Probst P, Peckham D, Muñoz-Elias EJ, Kruger JC, et al. Safety and pharmacodynamics of dalalazid, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. PLoS One. 2017;12:e0180762.

76. Pennington M, Chang S, Chauhan S, Hsu R, Tajhya R, Chhabra S, et al. Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide Shk. Mar Drugs. 2015;13:529–42.